Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Blood (2025) 146 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2025-2392

Published: 2025

Journal Articles

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Blood (2025) 146 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2025-1949

Published: 2025

Journal Articles

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

Blood (2025) 146 (Supplement 1): 503.

https://doi.org/10.1182/blood-2025-503

Published: 2025

Journal Articles

Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy

Dhyani Shah, Markus Perl, Matthias Fante, Severin Guetter, Simon Holzinger, Luisa-Marie Becker, Misbah Tariq, Philipp Meanauer, Simon Delahais, Gloria Lutzny-Geier, Julian Scherer, Sascha Goettert, Konstantin Herfeld, Paul Heinrich, Klaus-Georg Kreitmeier, Wolfgang Herr, Janina Doerr, Dennis Harrer, Leo Hansmann, Marcel Trefny, Matthias Edinger, Daniel Wolff, Daniela Weber, Elisabeth Meedt, André Gessner, Ernst Holler, Tobias Wertheimer, Klaus Neuhaus, Tingting Zheng, Kai Ziegler-Martin, David M. Cordas Dos Santos, Sebastian Theurich, Melanie Schirmer, Jonas Schluter, Michael Schmitt, Karin Kleigrewe, Markus Feuerer, Christoph Heuser-Loy, Jeremy Baldwin, Michael Hudecek, Luca Gattinoni, Marion Subklewe, Viktoria Blumenberg, Maria-Luisa Schubert, Christoph Stein-Thoeringer, Maik Luu, Sebastian Kobold, Erik Thiele Orberg, Hendrik Poeck

Blood (2025) 146 (Supplement 1): 2343.

https://doi.org/10.1182/blood-2025-2343

Published: 2025

Journal Articles

Adipose tissue-associated lipid serum signatures modulate efficacy and toxicity of CAR-T cell therapy in lymphoid malignancies

David Cordas Dos Santos, Hannah Thurisch, Jingke Tu, Daniel Heilpern-Mallory, Amar Hadzic, Martin Kirmaier, Werner Schmitz, Martin Vaeth, Sabine Oganesian, Adriano Carboniero, Ludovica Vona, Viktoria Blumenberg, Veit Buecklein, Michael Von Bergwelt, Kai Rejeski, Marion Subklewe, Sebastian Theurich

Blood (2025) 146 (Supplement 1): 5887.

https://doi.org/10.1182/blood-2025-5887

Published: 2025

Journal Articles

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance

Blood (2025) 146 (Supplement 1): 270.

https://doi.org/10.1182/blood-2025-270

Published: 2025

Journal Articles

Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment

Viktoria Blumenberg, Benjamin R. Puliafito, Charlotte E. Graham, Mark B. Leick, Md. Raihan Chowdhury, Maxx King, Deshea L. Harris, Noopur S. Raje, Andrew R. Branagan, Andrew J. Yee, Diana Cirstea, Kathleen M. E. Gallagher, Jörg Dietrich, Marcela V. Maus, Matthew J. Frigault

Blood (2025) 145 (23): 2788–2793.

https://doi.org/10.1182/blood.2024028172

Published: 2025

Includes: Supplemental data

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood (2025) 145 (8): 823–839.

https://doi.org/10.1182/blood.2024025366

Published: 2025

Includes: Supplemental data

Journal Articles

Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Viktoria Blumenberg, Maryam Kazerani, Tobias Straub, Francesco Corrado, Vadim Borisov, Stephan Baumann, Galina Busch, Jan Wulf, Agnese Petrera, Kai Rejeski, Christian Schmidt, Benjamin Tast, Michael von Bergwelt-Baildon, Christoph Stein-Thöringer, Veit L. Buecklein, Marion Subklewe

Blood (2024) 144 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2024-208938

Published: 2024

Journal Articles

Evaluation of the Individual Components of the International Metabolic Prognostic Index (IMPI) in the Context of CAR T-Cell Treatment of Lymphoma

Michael Winkelmann, Kai Rejeski, Viktoria Blumenberg, Gabriel Sheikh, Veit L. Buecklein, Matthias Brendel, Michael Von Bergwelt, Marion Subklewe, Wolfgang G Kunz

Blood (2024) 144 (Supplement 1): 7508.

https://doi.org/10.1182/blood-2024-207418

Published: 2024

Journal Articles

Predictive Value of Maximum Tumor Dissemination (Dmax) in Lymphoma Patients Treated with CD19 Specific CAR T-Cell Therapy

Wolfgang G Kunz, Viktoria Blumenberg, Kai Rejeski, Gabriel Sheik, Matthias Brendel, Michael Von Bergwelt, Marion Subklewe, Michael Winkelmann

Blood (2024) 144 (Supplement 1): 6552.

https://doi.org/10.1182/blood-2024-209594

Published: 2024

Journal Articles

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Blood (2024) 144 (Supplement 1): 7126.

https://doi.org/10.1182/blood-2024-194895

Published: 2024

Journal Articles

Characterizing Environmental Adaption and Virulence of Gut Microbiome Enterococcus Spp. from Patients Receiving CD19-Targeted CAR-T Cell Therapy

Niklas Deschl, Viktoria Blumenberg, Maria-Luisa Schubert, Anita Schmitt, Michael Schmitt, Marion Subklewe, Christoph Stein-Thoeringer

Blood (2024) 144 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2024-205390

Published: 2024

Journal Articles

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

Francesco Corrado, Jan Wulf, Tobias Straub, Daniel Nixdorf, Anetta Marcinek, Nora Philipp, Chang-Feng Chu, Christina Zielinski, Michael von Bergwelt-Baildon, Viktoria Blumenberg, Maryam Kazerani, Marion Subklewe, Veit L. Buecklein

Blood (2023) 142 (Supplement 1): 600.

https://doi.org/10.1182/blood-2023-188970

Published: 2023

Journal Articles

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Viktoria Blumenberg, Maryam Kazerani, Stephan Baumann, Tobias Straub, Francesco Corrado, Jan Wulf, Galina Busch, Kai Rejeski, Lisa Frölich, Christian Schmidt, Michael von Bergwelt-Baildon, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2023-187495

Published: 2023

Journal Articles

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

David M. Cordas dos Santos, Amar Hadzic, Martin E. Kirmaier, Werner Schmitz, Viktoria Blumenberg, Kai Rejeski, Veit L. Buecklein, Michael von Bergwelt-Baildon, Marion Subklewe, Sebastian Theurich

Blood (2023) 142 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2023-186178

Published: 2023

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

Journal Articles

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

Kai Rejeski, Zhijie Wu, Viktoria Blumenberg, Wolfgang G. Kunz, Susanna Müller, Sachiko Kajigaya, Shouguo Gao, Veit L. Bücklein, Lisa Frölich, Christian Schmidt, Michael von Bergwelt-Baildon, Xingmin Feng, Neal S. Young, Marion Subklewe

Blood (2022) 140 (20): 2175–2179.

https://doi.org/10.1182/blood.2022017015

Published: 2022

Includes: Supplemental data

Journal Articles

Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy

Kai Rejeski, David M. Cordas dos Santos, Paul Trinkner, Sophie Guenther, Lian Liu, Michael Winkelmann, Veit L Buecklein, Viktoria Blumenberg, Christian Schmidt, Philipp Karschnia, Wolfgang G. Kunz, Michael von Bergwelt, Sebastian Theurich, Marion Subklewe

Blood (2022) 140 (Supplement 1): 10405–10406.

https://doi.org/10.1182/blood-2022-159493

Published: 2022

Journal Articles

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

Hannah Reimann, Anita Natalie Kremer, Viktoria Blumenberg, Katja Schmidt, Michael Aigner, Andreas Kremer, Matthias Tenbusch, Heiko Bruns, Thomas Harrer, Georg Schett, Fabian Mueller, Andreas Mackensen, Marion Subklewe, Simon Voelkl

Blood (2022) 140 (Supplement 1): 10279–10280.

https://doi.org/10.1182/blood-2022-165968

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy

Adipose tissue-associated lipid serum signatures modulate efficacy and toxicity of CAR-T cell therapy in lymphoid malignancies

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance

Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Evaluation of the Individual Components of the International Metabolic Prognostic Index (IMPI) in the Context of CAR T-Cell Treatment of Lymphoma

Predictive Value of Maximum Tumor Dissemination (Dmax) in Lymphoma Patients Treated with CD19 Specific CAR T-Cell Therapy

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Characterizing Environmental Adaption and Virulence of Gut Microbiome Enterococcus Spp. from Patients Receiving CD19-Targeted CAR-T Cell Therapy

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only